Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Editorial Examines How USAID Programs Used Biblical Lessons To Teach Abstinence In Africa
A recent audit by the U.S. Agency for International Development"s inspector general has "raised questions about several USAID expenditures" on a number of "faith-based" projects initiated during former President George W. Bush"s administration, a Los Angeles Times editorial says. Among other issues, the report highlighted "the use of instructional materials, including biblical references," in an HIV/AIDS prevention program that promoted sexual abstinence in Africa, the editorial continues. It adds that USAID said that it "stopped allowing "religiously infused" curricula after the Justice Department expressed legal qualms."According to the Times, the issue raises several questions, including whether the U.S. Constitution is "violated when U.S. officials abroad ... endorse religious activities in the furtherance of this nation"s foreign policy." It states, "Our answer is no, but policymakers still need to be cautious about mixing religion and diplomacy" (Los Angeles Times, 7/24).
generic viagra online
New Cognitive Screening Test For Detecting Early Dementia
Researchers at Addenbrook"s Hospital in Cambridge published a study on bmj.com in which they explain their design and evaluation of a new cognitive test for detecting Alzeimer" disease called TYM ("test your memory") which is considered quicker and more precise than many existing tests, and which can also help diagnose early dementia.
News of the day
Dental Technology Can Help Reduce Patients In-Office Time
Technology is the way of the future, or at least the way of the American future, which is why dentists throughout the United States have increased their use of digital technology. And as making a better use of patients" two most useful res: time and money becomes increasingly important in the practice of dentistry, technology becomes the key to success. Dennis J. Fasbinder, DDS, MAGD, ABGD will help dentists decrease the amount of time that patients" spend in the office by leading a discussion and providing information about using computer-assisted design and computer-assisted machining (CAD/CAM) technology at the Academy of General Dentistry"s (AGD) 57th Annual Meeting, which is taking place in Baltimore, Md., July 8 - 12, 2009.
Cardiovascular

Project Zero Delay Accelerates Drug's Path To Clinical Trial

A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd. The joint effort, dubbed Project Zero Delay, is part of a strategic collaboration between the two organizations designed to safely accelerate development of new cancer drugs. In many cases that process takes about 12 years and the cost of bringing a new drug to patients has been estimated at around $1.3 billion. [Ref: J. A. DiMasi and H. G. Grabowski, "The Cost of Biopharmaceutical R&D: Is Biotech Different?" Managerial and Decision Economics 28 (2007): 469-479.] "Project Zero Delay demonstrates how we can shrink the time it takes to bring new drugs to cancer patients," said Robert C. Bast Jr., M.D., vice president for translational research at M. D. Anderson and the paper"s senior author. "We need to find out as promptly as possible whether new therapies will help. Zero Delay is a significant step in that direction. Close cooperation allowed us to eliminate unnecessary delays while fully meeting regulatory requirements for scientific and human safety review." The key to Zero Delay was performing most tasks in parallel instead of sequentially, said lead author Razelle Kurzrock, M.D., professor and chair of M. D. Anderson"s Department of Investigational Therapeutics. In addition, tasks usually done after FDA clearance of an Investigational New Drug (IND) application were instead done in advance. No administrative steps were skipped. This approach can be applied in other areas of drug development and by other institutions willing to cooperate closely, the authors note. "Zero Delay addressed one aspect of drug development - clinical trial start-up time," Kurzrock said. "Substantial time could be cut from other steps by applying the same principles." The time between having a complete written protocol and enrollment of the first patient is typically 135 days in M. D. Anderson"s Phase I Clinical Trial Program when processing of the protocol starts after IND approval. Zero Delay went from having a complete written protocol to first patient in 46 days, with FDA clearance of the IND on day 44. Research elsewhere cited in the Zero Delay paper indicates enrollment of the first patient after having a final protocol typically takes 3-6 months. Administrative tasks accomplished before the FDA"s ruling included budget and contract negotiations, site visits and preparation, training and a series of mandatory institutional reviews at M. D. Anderson. "M.D. Anderson and AstraZeneca share a common goal of using leading edge science to deliver medicines that will benefit patients now and in the future, while speeding up the process and making it more cost efficient," said Alan Barge, vice president and Head of Oncology at AstraZeneca. "AZ is always looking to improve our processes and to optimize value along our pipeline. This achievement is a great example of what can be accomplished when we pair our first class internal capabilities with the strengths of one of our key alliance partners in the U.S." In 2005, M. D. Anderson and AstraZeneca established a strategic alliance that includes a master agreement for clinical and translational/preclinical research specifying terms for standard items that can cause lengthy negotiations. The master agreement ensures that new research projects and clinical trials are initiated without delays caused by contracting issues. New clinical trials can simply be appended to an existing master agreement, often as quickly as in a day. "Zero Delay demonstrates what can be accomplished in an atmosphere of trust and collaboration that we"ve cultivated through our strategic alliance," Bast said. The alliance agreement also includes a commitment to regular meetings, a point of contact to remove obstacles, support of collaborative projects and a commitment to accelerate drug development. "The next challenge, said Barge, will be to do this consistently in order to develop truly innovative therapies that will someday offer new benefits to cancer patients." Co-authors with Kurzrock and Bast are: Susan Pilat, Marcel Bartolazzi, and Dwana Sanders, all of M. D. Anderson"s Department of Investigational Therapeutics; Stanley Tucker, Ph.D., Office of Translational Research. From AstraZeneca: Jill Hood, Ph.D., Kevin Webster, Michael Mallamaci, Steven Strand and Eileen Babcock. Robyn Stein University of Texas M. D. Anderson Cancer Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009